Recent Company News

• 09:20 AM ET Feb 24, 2026
  

  StreetAccount Summary - US Pre-market trading update

• 08:27 AM ET Feb 24, 2026
  

  StreetAccount Summary - US Pre-market trading

• 06:44 AM ET Feb 24, 2026
  

  Abivax initiated underperform at Wedbush Securities ($132.91, 0.00)

• 10:13 AM ET Feb 21, 2026
  

  Abivax presents first evidence of anti-fibrotic activity for Obefazimod alongside new clinical efficacy and safety analyses in inflammatory bowel disease at ECCO 2026 (€112.40, 0.00)

• 08:58 AM ET Feb 18, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 05:28 PM ET Feb 17, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market